Drastic price cut will weaken Korea’s R&D capability
Published: 2011-10-12 06:59:00
Updated: 2011-10-12 06:59:00
The Korea Pharmaceutical Manufacturers Association said Monday that a drastic price cut would make domestic drug producers unable to invest in research and development (R&D), which is persuasive, given that they cannot invest much in R&D when they had the resources.
The KPMA said it will wipe ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
